WEST HILLS, California, May 31, 2011 /PRNewswire/ — Medical Compression
Systems (MCS), which is involved in the non-invasive medical device industry
and traded on the TASE, announced today that it has received FDA clearance to
market the ActiveCare+Dx (temporary name) device developed on the basis of
its flagship product, ActiveCare+S.F.T.(R)

The new product is the only one on the market which integrates venous
obstruction prevention and detection capacities whereby both operations are
carried out simultaneously during prophylactic therapy. This device detects
venous obstructions in the patients’ circulation whilst they occur and alerts
about their formation. Currently, there is a 5%-6% risk of DVT formation
amongst post-orthopedic surgery patients undergoing preventive drug or device
therapy or a combination of the two. However, there is no drug or technology
that has the capability to alert on prevention failure, which as stated
above, occurs in 5%-6%. Using MCS’s device will allow quicker identification
of these patients and earlier treatment to begin, immediately after the
presence of a blood clot is verified. Starting the therapy early could
substantially reduce the occurrence of possible serious risks such as
pulmonary embolism, which could be fatal.

The advantages of the company’s flagship product, ActiveCare+S.F.T., over
the leading DVT prevention drug, Lovenox, have already been proven in a
multicenter clinical trial that was conducted by MCS on hip replacement
patients in the US. The new device provides another advantage for MCS over
the use of medication by providing early detection of those patients in whom
preventive treatment has failed.

According to Adi Dagan, MCS CEO: “We are happy to receive FDA clearance
for ActiveCare+Dx. This product meets a significant need, especially in the
market of DVT prevention, where complications could be fatal. About ninety
percent of the DVT cases are invisible and will not be diagnosed until
clinical signs and symptoms are already presented. Their first presenting
symptom can be pulmonary embolism or death. The product is expected to enter
the market during the course of 2012.”

About Medical Compressions Systems (MCS)

Medical Compression Systems (MCS) is a leader in innovative, non-invasive
solutions for the prevention of venous thromboembolism (VTE). The company is
the first and currently the only to offer the healthcare market a new class
of proven Continuous Enhanced Circulation Therapy in combination with MCS’s
patented Synchronized Flow Technology (C.E.C.T.(R) + S.F.T.) devices that can
replace pharmaceutical therapy as the current standard of care.

The company’s products have US FDA clearance and are CE approved; its
products are protected by numerous patents.

Founded in1997, MCS Medical Compression Systems (Ltd.), is an Israeli
public company, traded on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc.,
the company’s subsidiary, is located in the USA.

Forward looking information

The company’s evaluations included in the article, including its
anticipated scope of operations, is forward looking information as defined in
the Securities Law, 5728-1968 and it is uncertain whether this information
will materialize. These evaluations are based on business assumptions, past
experience and professional information.

These evaluations might not materialize, in full or in part, or may
materialize substantially different to the company’s expectations for various
reasons, including changes in market trends, competition, the global or
domestic economic situation, and regulatory changes.

    Media Contact:
    Vered Rahat-Roth,
    Tel. +972-077-4330470, +972-(0)52-8000380
    Email. vered.rahat@gmail.com

SOURCE Medical Compression System Ltd